Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b open-label single-arm study of olorofim for invasive fungal infections with limited treatment options
MOH_2019-08-25_007361Phase 2Not yet recruiting
- Sponsor
- F2G
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olorofim in invasive mycoses, aspergillosis, allescheriosis and 1 more, sponsored by F2G. Primary endpoint: Efficacy as determined by Data Review Committee. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
olorofim
03
Conditions
invasive mycosesaspergillosisallescheriosislomentosporiosis
Beyond the preview
Go deeper on MOH_2019-08-25_007361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-25_007361.